Outcome measures in CIDP: A scoping and mapping review
Substantial heterogeneity in CIDP COAs use exists. This review identified the INCAT, I-RODS, and MRC score as core measures that evaluate important, although not exhaustive, aspects of CIDP disease experience. The absence of validated CIDP biomarkers, and the heterogeneity of available COAs, may impact the assessment of CIDP treatment effectiveness. More research is needed to establish a set of comprehensive outcome measures, that are relevant to clinicians and patients with CIDP.
Authors
- Eduardo Nobile‐Orazio (ORCID: https://orcid.org/0000-0003-2624-8138)
- Yusuf A. Rajabally (ORCID: https://orcid.org/0000-0002-7170-8343)
- Wim Noël (ORCID: https://orcid.org/0000-0002-5988-4627)
- David M. Riley (ORCID: https://orcid.org/0000-0003-1072-6027)
- Soraya Riley (ORCID: https://orcid.org/0009-0003-3475-1187)
- Giorgio Maria Boggia
- Judith Peatman
- Charlotte Gary
Institutions
- Johnson & Johnson (United States) (US)
- Humanitas University (IT)
- Aston University (GB)
- Adelphi Group (United Kingdom) (GB)
- IRCCS Humanitas Research Hospital (IT)
Publication Details
- Journal
- Journal of the Neurological Sciences
- Published
- 2025-08-12
- DOI
- https://doi.org/10.1016/j.jns.2025.123654
- Primary Topic
- Peripheral Neuropathies and Disorders
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Johnson and Johnson